Anti-Desmoglein 3 Antibody

<strong>anti-Desmoglein 3 Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2014758_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8 ¬∞C_x000D_ <strong>Keywords:</strong> 130 kDa pemphigus vulgaris antigen;cadherin family member 6;CDHF6;desmoglein-3;PVA_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, Amagai M. Pemphigus Nat Rev Dis Primers. 2017 May 11;3:17026._x000D_ 2: Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, Aburatani H, Suzuki M. Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma J Biochem. 2018 Dec 1;164(6):471-481._x000D_ 3: Yamamoto Y, Aoyama Y, Shu E, Tsunoda K, Amagai M, Kitajima Y. Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity J Biol Chem. 2007 Jun 15;282(24):17866-76._x000D_ 4: Yamamoto Y, Aoyama Y, Shu E, Tsunoda K, Amagai M, Kitajima Y. No activation of urokinase plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured human keratinocytes J Dermatol Sci. 2007 Aug;47(2):119-25._x000D_ 5: Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation J Invest Dermatol. 2006 Dec;126(12):2621-30._x000D_ 6: Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, David M, Shoenfeld Y. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris Clin Exp Immunol. 2010 Dec;162(3):543-9._x000D_ 7: Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris Exp Dermatol. 2013 Nov;22(11):699-704._x000D_ 8: Stanley JR, Ishii K, Siegel DL, Payne AS. Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy Vet Dermatol. 2009 Oct;20(5-6):327-30._x000D_ 9: Sharma PM, Choi EJ, Kuroda K, Hachiya T, Ishii K, Payne AS. Pathogenic anti-desmoglein MAbs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3 J Invest Dermatol. 2009 Sep;129(9):2309-12._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/23949768">10: Sadik CD, Zillikens D. Skin-specific drug delivery: a rapid solution to skin diseases? J Invest Dermatol. 2013 Sep;133(9):2135-7. </a>_x000D_ _x000D_ <strong>Products Related to anti-Desmoglein 3 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>